Revision: June 22, 2026, 12:15 p.m.
June 22, 2026
2026-2184-EBA
09/07
Enrolled Bill Amendment to HB 1772-FN-A
The Committee on Enrolled Bills to which was referred HB 1772-FN-A
AN ACT relative to prescribing ibogaine for investigational use only and adopting the physician associate licensure compact.
Having considered the same, report the same with the following amendment, and the recommendation that the bill as amended ought to pass.
FOR THE COMMITTEE
__________________________________
─────────────────────────────────────────────────────────────────
Explanation to Enrolled Bill Amendment to HB 1772-FN-A
This enrolled bill amendment makes a technical correction and grammatical corrections to the bill.
Enrolled Bill Amendment to HB 1772-FN-A
Amend section 1 of the bill by replacing lines 1-2 with the following:
1 New Subdivision; Ibogaine; Administered Under FDA-Approved Research Protocol. Amend RSA 329 by inserting after section 1-h the following new subdivision:
Ibogaine; Administered Under FDA-Approved Research Protocol
Amend RSA 328-D:18-a, 9.B. as inserted by section 2 of the bill by replacing line 3 with the following:
invalid and have no force or effect only if a court of competent jurisdiction holds that the rule is
Amend RSA 328-D:18-a, 9.D. as inserted by section 2 of the bill by replacing line 1 with the following:
D. If a majority of the legislatures of the participating states reject a commission rule, by